Anne Favret, MD
Medical Oncology · Fairfax, VANPI 1205803202
Payments from drug & device makers
Across 576 payments — averaging $3213.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$628K
- Pfizer$521K
- AstraZeneca$385K
- Seagen Inc.$129K
- Eli Lilly$121K
- Gilead$19K
- plus $49K from 9 others
Across 4 payments — averaging $510.79 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$2K
- Eli Lilly$21
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 375 | $627,559 |
| Pfizer | 69 | $521,127 |
| AstraZeneca | 12 | $384,694 |
| Seagen Inc. | 76 | $128,612 |
| Eli Lilly | 10 | $120,822 |
| Gilead | 9 | $18,967 |
| Novartis | 7 | $18,089 |
| Veru Inc. | 4 | $17,458 |
| G1 Therapeutics, Inc. | 6 | $13,625 |
| Bioprotect Medical, Inc. | 2 | $155 |
| Daiichi Sankyo Inc. | 2 | $43 |
| Myriad Genetic Laboratories, Inc. | 1 | $34 |
| Johnson & Johnson | 1 | $20 |
| Bristol Myers Squibb | 1 | $19 |
| Medtronic | 1 | $19 |
How this compares
$1,851,243 in reported general payments places this provider in the 85th percentile of 95 medical oncology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Fairfax
- Alexander SpiraFairfax$69.5M
- Kathleen HarndenFairfax$4M
- Adam CohenFairfax$2.2M
- Janakiraman SubramanianFairfax$1.9M
- Timothy CannonFairfax$1.9M
- John DeekenFairfax$1.6M
- Arthur WinerFairfax$923K
- Nagla Abdel KarimFairfax$911K
- Amin BenyounesFairfax$824K
- Eun-Mi YuFairfax$529K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.